靶向肿瘤免疫微环境放射性药物研究进展  

Research progress in radiopharmaceuticals targeting tumor immune microenvironment

作　　者：朱凯 刘彩云 辛文斌 刘婷婷[2] 王旭[1] Zhu Kai;Liu Caiyun;Xin Wenbin;Liu Tingting;Wang Xu(Department of Nuclear Medicine,Binzhou Medical University Hospital,Binzhou 256603,China;Medical Research Center,Binzhou Medical University Hospital,Binzhou 256603,China)

机构地区：[1]滨州医学院附属医院核医学科,滨州256603 [2]滨州医学院附属医院医学研究中心,滨州256603

出　　处：《中华核医学与分子影像杂志》2024年第9期559-563,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金(81771828);山东省高校科研计划(J18KB116);滨州医学院科技计划项目(BY2022KJ42)。

摘　　要：免疫治疗在肿瘤治疗领域取得了突破性的进展。如何在早期精确预测肿瘤患者对免疫治疗的响应是目前临床所面临的挑战。核医学分子影像为疾病的早期精确诊断、治疗监测, 复发和转移预警以及个体化治疗指导提供了崭新的技术手段, 因此在肿瘤的精准诊治及患者分层中发挥着不可替代的作用。该文综述针对肿瘤微环境内免疫细胞和相关靶点的分子影像研究进展。Immunotherapy has made breakthrough in the field of tumor treatment.How to accurately predict the response of tumor patients to immunotherapy in the early stage is currently a clinical challenge.Nuclear medicine molecular imaging provides a new technological means for early accurate diagnosis,treatment monitoring,early warning of recurrence and metastasis,and guidance for personalized treatment of diseases.Therefore,it plays an irreplaceable role in precise diagnosis and treatment of tumors and patient stratification.This article reviews the progress of molecular imaging research on immune cells and related targets within the tumor microenvironment.

关 键 词：放射性药物 免疫疗法 肿瘤微环境 发展趋势 

分 类 号：R730.51[医药卫生—肿瘤]